secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K/A
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001628280-24-029561
Event type: other_material
Sentiment:  negative
Materiality: 0.50
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo amends 8K to restate AlmataBio 2023 financials; net loss up $153K
-----------------------------------------------------------------------

- Restated AlmataBio net loss for April 28–Dec 31, 2023 to $812K from $659K, a $153K increase.
- R&D expense corrected upward by $135K to $663K; G&A expense up $18K to $149K.
- Restatement had no cash flow impact; cash and equivalents remained $1.767M at Dec 31, 2023.
- Previously issued financials for AlmataBio are superseded by this restated filing.
- Acquisition of AlmataBio by Avalo closed on March 27, 2024; this is Amendment No. 2 to the original 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024029561/0001628280-24-029561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024029561/avtx-20240327.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-029561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer